Bradykinin B2 Receptor Agonist

B2R Agonist for Temporary Permeabilization of BBB

Product Description

Product: B2R Receptor Agonist: metabolically stable peptide based in licensed sequence that selectively activates the Bradykinin B2 receptor for in vivo and in vitro research
Sequence: H-Arg-Pro-Hyp-Gly-Thi-Ser-NChg-Thi-Arg-OH
Purity: Over 98%
Applications: Various applications such as research into new drugs for ischemia reperfusion and tools for preclinical research like opening of blood brain barrier for contrast/drug delivery or creation of control model for assessing effectiveness of the latter
Research Disciplines: Used in various research disciplines such as neurological disease, cancer, drug delivery, cardiovascular research, ischemia related organ damage, reperfusion injury
CAS#: 1159100-37-4
Molecular weight: 1129.5 Daltons
Chemical structure: B2R Agonist


Anticancer Drug Delivery into Brain Tumors

  1. Côté J, Savard M, Neugebauer W, Fortin D, Lepage M, Gobeil F. Dual kinin B1 and B2 receptor activation provides enhanced blood–brain barrier permeability and anticancer drug delivery into brain tumors. Cancer Biology & Therapy. 2013;14(9):806-811.

Cardiovascular Research

  1. Savard M, Labonté J, Dubuc C, Neugebauer W, D’Orléans-Juste P, Gobeil F Jr.Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist.Biol Chem. 2013 Mar;394(3):353-60.
  2. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens. 2010 May;23(5):562-8. doi: 10.1038/ajh.2010.20. Epub 2010 Feb 25.
  3. Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F Jr, Marre M, Bruneval P, Richer C, Roussel R, Alhenc-Gelas F, Bouby N. Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.


Transient Opening of Blood Brain Barrier for Drug Delivery and In Vivo Research

Chemical Opening of Blood Brain Barrier

Representative intravital confocal images of a mouse brain microvasculature following i.v. injection of FITC-Dextran (MW 2 MDa) (A) and 30 min post-injection of MediLumine’s B2R agonist (0.050 mg/kg or 1.25 μg/mouse) showing extrasavation of FITC-Dextran (B). Scale represents the intensity of fluorescence (Courtesy of Drs Martin Lepage and Fernand Gobeil).


Obtain up to 20% discount for your longitudinal in vivo studies. Click here to learn more about our Vision without Sacrifice Campaign.


Bradykinin B2 Receptor Agonist